ROCHE REGISTRATION LIMITED

NICE Unable to Recommend Atezolizumab for Untreated NSCLC Due to Lack of Submission

• NICE has terminated its appraisal of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer in patients unsuitable for platinum-doublet chemotherapy. • Roche Products declined to submit evidence for the appraisal, citing concerns that there would be insufficient data to demonstrate cost-effectiveness in the NHS setting. • The decision affects adult patients with advanced NSCLC who cannot receive standard platinum-based chemotherapy, limiting their treatment options in the UK healthcare system.